IP Library › Granted Patent US 10,584,145
Granted Patent B2
US 10,584,145 · App. 15/826,233 · Granted Mar 10, 2020

Process for preparation of sulfonylurea bile acid derivatives

Inventors: Guoqiang Wang (Belmont, MA); Yong He (Lexington, MA); Peng Dai (Auburndale, MA); Guoyou Xu (Framingham, MA); Bin Wang (Brighton, MA); Jiang Long (Wayland, MA); Yat Sun Or (Watertown, MA)
Assignee: Enanta Pharmaceuticals, Inc.
C07J41/0055C07J9/005C07J41/0088C07J51/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,584,145
App. No.
15/826,233
Granted
Mar 10, 2020
Kind
B2
Abstract

The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.

Claims (75)

1. A process for preparing an amorphous solid form of a compound of Formula I:

wherein

R 1 is selected from the group consisting of:

1) substituted or unsubstituted —C 1 -C 8 alkyl;

2) substituted or unsubstituted —C 2 -C 8 alkenyl;

3) substituted or unsubstituted —C 2 -C 8 alkynyl;

4) substituted or unsubstituted —C 3 -C 8 cycloalkyl;

5) substituted or unsubstituted aryl;

6) substituted or unsubstituted arylalkyl;

7) substituted or unsubstituted 3- to 12-membered heterocycloalkyl;

8) substituted or unsubstituted heteroaryl;

9) substituted or unsubstituted heteroarylalkyl; and

10)NR 2 R 3 ; wherein, R 2 and R 3 are each independently selected from hydrogen,substituted or unsubstituted —C 1 -C 8 alkyl, substituted or unsubstituted —C 2 -C 8 alkenyl, Substituted or unsubstituted —C 2 -C 8 alkynyl, substituted or unsubstituted —C 3 -C 8 cycloalkyl, alternatively R 2 and R 3 are taken together with the nitrogen atom to which they attached to form a 3- to 12-membered hetercyclic ring;

said process comprising the steps of:

a) reacting 7-keto lithocholic acid with a hydroxyl protecting reagent to produce compound 2;

wherein PG 1 is a hydroxyl protecting group;

b) reacting compound 2 with an acyl azide formation reagent in the presence of R 4 CH 2 OH to produce compound 3:

wherein R 4 is substituted or unsubstituted phenyl;

c) deprotecting compound 3 to produce compound 4:

d) reacting compound 4 with a silylating agent in the presence of a base to produce compound 5:

wherein PG 2 is a silyl group;

e) reacting compound 5 with acetaldehyde in the presence of a Lewis acid to produce compound 6:

f) hydrogenating compound 6 to produce compound 7:

g) reacting compound 7 with a base in a protic solvent or a mixture of a protic solvent and a non-protic solvent to produce compound 8:

h) reducing compound 8 to produce the compound (II):

i) optionally reacting compound (II) with HA, wherein HA is an acid, to form the salt 9,

j) reacting compound (II) or the salt 9 with a compound of formula 10E,

wherein R′ is imidazol-1-yl, alkyl-O- aryl-O-, Cl, or CCl 3 , in the presence of an organic base, to form the compound of Formula (I):

k) treating the compound of Formula (I) with diethyl amine to produce a compound of Formula (IV):

and

l) treating the compound of Formula (IV) with an acid, thereby producing the amorphous form of the compound of Formula (I).

2. The process of claim 1 , wherein R 1 is

3. The process of claim 1 , wherein in step a), the hydroxyl protecting reagent is tert-butyl(dimethyl)silyl chloride.

4. The process of claim 1 , wherein in step b), the acyl azide formation reagent is diphenylphosphoryl azide.

5. The process of claim 1 , wherein in step c), compound 3 is deprotected by reaction with HCl in methanol.

6. The process of claim 1 , wherein in step d), the silylating agent is trimethylsilyl trifluoromethanesulfonate.

7. The process of claim 1 , wherein in step e), the Lewis acid is BF 3 .Et 2 O.

8. The process of claim 1 , wherein in step g), the base is NaOH.

9. The process of claim 1 , wherein in step h), the reducing agent is NaBH 4 .

10. The process of claim 1 , wherein in step j) the compound of Formula 10E is of the formula

wherein R 1 is as defined in claim 1 .

11. The process of claim 2 , wherein in step j), the compound of Formula 10E is selected from compounds of formulas 10A, 10B, 10C and 10D:

wherein R 5 is alkyl or aryl.

12. A process for preparing an amorphous solid form of a compound of Formula I:

wherein

R 1 is selected from the group consisting of:

1) substituted or unsubstituted —C 1 -C 8 alkyl;

2) substituted or unsubstituted —C 2 -C 8 alkenyl;

3) substituted or unsubstituted —C 2 -C 8 alkynyl;

4) substituted or unsubstituted —C 3 -C 8 cycloalkyl;

5) substituted or unsubstituted aryl;

6) substituted or unsubstituted arylalkyl;

7) substituted or unsubstituted 3- to 12-membered heterocycloalkyl;

8) substituted or unsubstituted heteroaryl;

9) substituted or unsubstituted heteroarylalkyl; and

10) NR 2 R 3 ; wherein, R 2 and R 3 are each independently selected from hydrogen,substituted or unsubstituted —C 1 -C 8 alkyl, substituted or unsubstituted —C 2 -C 8 alkenyl, Substituted or unsubstituted —C 2 -C 8 alkynyl, substituted or unsubstituted —C 3 -C 8 cycloalkyl, alternatively R 2 and R 3 are taken together with the nitrogen atom to which they attached to form a 3- to 12-membered hetercyclic ring;

said process comprising the steps of:

a) treating the compound of Formula (I) with diethyl amine to produce a compound of Formula (IV):

and

b) treating the compound of Formula (IV) with an acid, thereby producing an amorphous form of the compound of Formula (I).

13. A process for producing compound (II),

comprising the steps of

a) reacting 7-keto lithocholic acid with a hydroxyl protecting reagent to produce compound 2;

wherein PG 1 is a hydroxyl protecting group;

b) reacting compound 2 with an acyl azide formation reagent in the presence of R 4 CH 2 OH to produce compound 3:

wherein R 4 is substituted or unsubstituted phenyl;

c) deprotecting compound 3 to produce compound 4:

d) reacting compound 4 with a silylating agent in the presence of a base to produce compound 5:

wherein PG 2 is a silyl group;

e) reacting compound 5 with acetaldehyde in the presence of a Lewis to produce compound 6:

f) hydrogenating compound 6 to produce compound 7:

g) reacting compound 7 with a base in a protic solvent or a mixture of a protic solvent and a non-protic solvent to produce compound 8:

and

h) reducing compound 8, thereby producing compound (II).

14. The process of claim 12 , wherein R 1 is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2018
From: WANG, GUOQIANG; HE, YONG; DAI, PENG; XU, GUOYOU; WANG, BIN; LONG, JIANG; OR, YAT SUN
To: ENANTA PHARMACEUTICALS, INC.
Reel/Frame 045396/0523 →
Continuity (2)
Provisional Application 62427354 · Nov 29, 2016
Related Publication 20180148469A1 · May 31, 2018
Cited By (1)
US 12,281,140